Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Endometrial Cancer: early-phase trial registry
108 of 188 indexed Endometrial Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #59 of 28,707 conditions by registered trial count.
188 US clinical trials · 108 currently recruiting · #59 of 28,707 conditions by registered trial count
Endometrial Cancer: 188 US clinical trials tracked, 108 recruiting.
Endometrial Cancer is the subject of 188 registered US clinical trials on ClinicalTrials.gov, 108 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 17 of these trials.
Enrollment posture brief
Registry condition endometrial-cancer
OPEN 108 | RECR 57% | LATE 15 | EARLY 118 | RANK #59 | SPON 17
Volume-matched condition peers
Nearest open-share peer: Mesothelioma (57% recruiting · 47 trials)
Endometrial Cancer lists 108 open slots (57% of 188 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Endometrial Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Endometrial Cancer is recruiting above its size-band peers.
108 of 188 indexed trials (57.4%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Endometrial Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 17 of 188 trials (9%). 116 distinct sponsors appear on at least one study for this condition label.
-
Typical Endometrial Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 182 trials that report a genuine target (sentinel values excluded). 85 of those (46.7%) plan for fewer than 100 participants.
-
Endometrial Cancer research is mostly interventional.
167 interventional and 21 observational studies make up this index (88.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
188 total, page 2 of 4
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
Northwestern University
NCT05743517
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
NCT03675893
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
NCT07262619
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo
NCT07182149
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Alliance Foundation Trials
NCT04486352
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure
NCT06774963
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06974110
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
NCT05856981
Mindfulness in Endometrial and Cervical Cancer
St. Louis University
NCT04512144
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
NCT06239194
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics
NCT06533059
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT06218914
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
University of Chicago
NCT04683653
DESTINY-PANTUMOUR04
AstraZeneca
NCT07124000
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT04969315
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05103683
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics
NCT06515613
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT07209449
ASk Questions in GYnecologic Oncology (ASQ-GYO)
Ira Winer
NCT06339827
Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)
Medtronic - MITG
NCT07120945
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
University of Utah
NCT05979610
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
NCT04774419
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Iovance Biotherapeutics
NCT06481592
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
NCT06253494
Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers
Jonsson Comprehensive Cancer Center
NCT06538337
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05542407
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
Alessandro Santin
NCT03832361
A Study of Ivonescimab in People With Endometrial and Cervical Cancers
Memorial Sloan Kettering Cancer Center
NCT06925724
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings
NCT04196257
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Medical College of Wisconsin
NCT07227077
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
M.D. Anderson Cancer Center
NCT06409052
Vaginal Fluid Collection for Detection of Endometrial Cancer
Innovis
NCT06294886
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Faeth Therapeutics
NCT06463028
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
NCT05559879
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Washington University School of Medicine
NCT06795009
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT06751589
The Better, Harder, Faster, Stronger Study
Wake Forest University Health Sciences
NCT07220512
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
NCT06366347
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT07270666
Multimedia Aid for Genetic Testing in Gynecologic Oncology
UNC Lineberger Comprehensive Cancer Center
NCT07084168
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
Northwestern University
NCT05990426
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Dana-Farber Cancer Institute
NCT04997096
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience
NCT05997017
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
NCT05691010
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 74 |
| Phase 2 | 44 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Endometrial Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Endometrial Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Endometrial Cancer page
188 registered trials, 108 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 108 Endometrial Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Endometrial Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Endometrial Cancer condition card totals 188 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.